The impact of initiating rivaroxaban versus low-molecular weight heparin plus warfarin in patients admitted to the hospital for venous thromboembolism

被引：2
|
作者：
Hom, Lindsay [1 ]
Sobieraj, Diana M. [2 ]
机构：
[1] Hartford Hosp, Serv Pharm, Hartford, CT 06102 USA
[2] Univ Connecticut, Sch Pharm, Dept Pharm Practice, Storrs, CT 06269 USA
来源：
INTERNATIONAL JOURNAL OF CARDIOLOGY | 2015年 / 198卷
关键词：
Venous thromboembolism; Anticoagulant; Rivaroxaban; DEEP-VEIN THROMBOSIS; LENGTH-OF-STAY;
D O I：
10.1016/j.ijcard.2015.06.060
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：87 / 88
页数：2
相关论文
共 50 条
  • [41] Impact of apixaban vs low molecular weight heparin/vitamin k antagonist on hospital resource use in patients with venous thromboembolism
    Browne, C.
    Lanitis, T.
    Hamilton, M.
    Li, X.
    Horbyluk, R.
    Mardekian, J.
    Kongnakorn, T.
    Cohen, A.
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (01) : 98 - 106
  • [42] Low-molecular-weight Heparin (enoxaparin) versus unfractionated heparin for venous thromboembolism prophylaxis in patients undergoing craniotomy
    Kandula, Viswajit
    Shah, Parth, V
    Thirunavu, Vineeth M.
    Yerneni, Ketan
    Karras, Constantine
    Abecassis, Zachary A.
    Hopkins, Benjamin
    Bloch, Orin
    Potts, Matthew B.
    Jahromi, Babak S.
    Tate, Matthew C.
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2022, 223
  • [43] Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients: a pharmacoeconomic analysis
    Wilbur, Kerry
    Lynd, Larry
    Sadatsafavi, Mohsen
    PHARMACY WORLD & SCIENCE, 2009, 31 (02): : 266 - 266
  • [44] Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer
    Lee, AYY
    Levine, MN
    Baker, RI
    Bowden, C
    Kakkar, AK
    Prins, M
    Rickles, FR
    Julian, JA
    Haley, S
    Kovacs, MJ
    Gent, M
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (02): : 146 - 153
  • [45] Heparin and low-molecular-weight heparin in the treatment of venous thromboembolism
    Pineo, GF
    Hull, RD
    BAILLIERES CLINICAL HAEMATOLOGY, 1998, 11 (03): : 621 - 637
  • [46] Peri-procedural bridging with low molecular weight heparin in patients receiving warfarin for venous thromboembolism: A pediatric experience
    Moruf, A.
    Spyropoulos, A. C.
    Schardt, T. Q.
    Gibson, E.
    Manco-Johnson, M. J.
    Wang, M.
    Goldenberg, N. A.
    THROMBOSIS RESEARCH, 2012, 130 (04) : 612 - 615
  • [47] Is low-molecular-weight heparin safer than warfarin for secondary prevention of venous thromboembolism in cancer patients? Reply
    Meyer, G
    Farge, D
    ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (10) : 1244 - 1244
  • [48] Cost effectiveness of low-molecular weight heparin versus warfarin following hip replacement surgery
    Saunders, ME
    Grant, RE
    JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 1998, 90 (11) : 677 - 680
  • [49] Aspirin versus low molecular weight heparin for secondary prevention of venous thromboembolism in pregnancy
    Soliman, Reem
    Soliman, Mosaad
    Elsaadany, Nashaat
    Abdelmaksoud, Mohamed A.
    Elkassaby, Mohamed
    EGYPTIAN JOURNAL OF SURGERY, 2025, 44 (01): : 43 - 49
  • [50] Low-molecular-weight heparin prescribing for venous thromboembolism in cancer patients
    Stewart, David
    Rikhye, Somi
    Odle, Brian
    Flores, Emily
    PHARMACOTHERAPY, 2013, 33 (05): : E51 - E51
12345